BioSpace News Archive

Additional 40mg/kg adult cohort demonstrates incremental efficacy; data reinforces AT-007 favorable safety and efficacy profile

Trial met primary endpoint with a strong relationship between Immunoglobulin G (IgG) reduction and MG-ADL clinical benefit (p<0.0001)

Primary composite first and total major adverse cardiovascular event (MACE) reductions of 23% each shown with VASCEPA in prespecified tertiary and post hoc exploratory analyses of the subgroup of people with diabetes

Designation follows recent announcement on development of first companion diagnostic using the Oncomine Precision Assay on the new Ion Torrent Genexus System

OTC Markets Group Inc., operator of financial markets for 10,000 U.S. and global securities, announced Appili Therapeutics Inc., a biopharmaceutical company focused on anti-infective drug development, has qualified to trade on the OTCQX® Best Market.

Preclinical data for Sanofi’s investigational compounds in breast, lung, multiple myeloma and other cancers will be featured at the American Academy of Cancer Research Virtual Annual Meeting II on June 22-24.

Marie France Quillen leads Azzur Labs Raleigh, which opened its doors in November 2018 to serve the growing needs of RTP industries

The long-term brain health supplement developed in partnership with the University of Oxford

Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received FDA 510(k) clearance to market and sell Venus Epileve

ContraFect Corporation, a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announced the appointment of Lishan Aklog, M.D. to the Company’s board of directors.